


Technology Advisory Committee C Interests Register

Topic: Venetoclax for treating chronic lymphocytic leukaemia (CDF review of TA487) [ID3886]

Publication Date: 15 June 2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Michael Chambers	Committee member	Direct - financial	Mr Chambers has participated in an advisory panel for Pfizer, manufacturer of a possible comparator therapy, but in an unrelated disease area (prostate cancer).	N/A	18.02.2022	N/A	It was agreed his declaration would not prevent Mr Chambers from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee member	Direct - financial	Dr Nicholas participated on advisory boards for Roche, manufacturer of a possible comparator therapy, but in an unrelated area (multiple sclerosis).	N/A	02.03.2022	N/A	It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.
Professor Adrian Bloor	Clinical expert	Direct - financial	Professor Bloor has received consultancy, speaker, advisory board fees and conference funding from AbbVie, Janssen, Gilead, Novartis, and Roche.	N/A	12.11.2021	N/A	It was agreed his declaration would not prevent Professor Bloor from providing expert advice to the committee.



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Peter Hillmen	Clinical expert	Direct & indirect financial	Professor Hillmen has received honoraria for lecturing and advisory boards from Abbvie, Janssen, Pharmacyclics, AstraZeneca, Beigene and Roche.	N/A	12.11.2021	N/A	It was agreed his declaration would not prevent Professor Hillmen from providing expert advice to the committee.
			His Institution, the University of Leeds, has received research support from Abbvie, Janssen, Pharmacyclics, Gilead and Roche.				
			He also chairs IWCLL which has received support from Abbvie, Janssen, Pharmacyclics, AstraZeneca, Beigene and Roche.				
Nick York	Patient expert	Non-financial professional, personal & indirect financial	Nick York is a patient advocate for Leukaemia Care. Leukaemia Care has received unconditional funding grants from AbbVie and most of the comparator companies.	N/A	11.02.2022	N/A	It was agreed his declaration would not prevent Nick from providing expert advice to the committee.